Physician profile
Gregory Sims
NPI 1669937199
$7,944.96
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $3,053 · 2023: $2,800 · 2024: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898 · Travel and Lodging: $886 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.43 |
| Travel and Lodging | $885.86 |
| Education | $116.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,508.92 | 2021-2023 | |
| Intuitive Surgical, INC. | $1,013.86 | 2024 | |
| Janssen Biotech, INC. | $647.82 | 2021-2023 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $598.01 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $557.50 | 2021-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $525.98 | 2022-2023 | Xifaxan, Trulance |
| Genzyme Corporation | $304.91 | 2022-2023 | |
| Celgene Corporation | $284.83 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $238.64 | 2022-2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $178.95 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $160.63 | 2021-2023 | Ocaliva |
| Lilly USA, LLC | $159.05 | 2023-2024 | Mounjaro |
| Qol Medical, LLC | $122.49 | 2021-2023 | Sucraid |
| Ardelyx, INC. | $120.98 | 2022-2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $118.16 | 2021-2023 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $115.24 | 2023 | |
| Pfizer INC. | $73.21 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $64.18 | 2022-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.08 | 2023 | Cyltezo |
| Amgen INC. | $39.53 | 2022-2023 | Amjevita, Avsola |
| Daiichi Sankyo INC. | $19.30 | 2022 | |
| Optinose US, INC. | $17.18 | 2021 | |
| Shield Therapeutics INC | $16.83 | 2023 | Accrufer |
| Intersect Ent, INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.